Original language | English (US) |
---|---|
Pages (from-to) | 970-971 |
Number of pages | 2 |
Journal | The Lancet Neurology |
Volume | 19 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2020 |
ASJC Scopus subject areas
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet Neurology, Vol. 19, No. 12, 12.2020, p. 970-971.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
AU - CARE-MG Study Group
AU - Muppidi, Srikanth
AU - Guptill, Jeffrey T.
AU - Jacob, Saiju
AU - Li, Yingkai Li
AU - Farrugia, Maria E.
AU - Guidon, Amanda C.
AU - Tavee, Jinny O.
AU - Kaminski, Henry
AU - Howard, James F.
AU - Cutter, Gary R.
AU - Wiendl, Heinz
AU - Maas, Matthew B.
AU - Illa, Isabel
AU - Mantegazza, Renato E.
AU - Murai, Hiroyuki
AU - Utsugisawa, Kimiaki
AU - Nowak, Richard J.
AU - Tyagi, Alok
AU - Sousa, Ana Paula
AU - Amato, Anthony A.
AU - Pinto, Ashwin
AU - Roy, Bhaskar
AU - Carmichael, Caroline
AU - Dodig, Dubravka
AU - Burke, Georgina
AU - Lee, Ikjae
AU - Caress, James
AU - Pritchard, Jane
AU - Vissing, John
AU - Best, Kamla
AU - Ramezani, Mahtab
AU - Hehir, Michael K.
AU - Kaku, Michelle
AU - Esquivel, Natalia Jiménez
AU - Gallagher, Paul
AU - Maddison, Paul
AU - Ambrose, Philip A.
AU - Do Campo, Rocio Vazquez
AU - Saba, Sami
AU - Nafissi, Shahriar
AU - Itoyama, Shannon
AU - Viegas, Stuart Viegas
AU - Marshall, Victoria
N1 - Funding Information: SM reports consultation fees for advisory board meetings from Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals, unrelated to this Correspondence. JTG reports personal fees for advisory boards from Immunovant, Alexion Pharmaceuticals, Cabaletta Bio, Regeneron Pharmaceuticals, argenx, and Momenta Pharmaceuticals and grants from Ra Pharmaceuticals, unrelated to this Correspondence. SJ has served as an international advisory board member for Alexion Pharmaceuticals, Alnylam Pharmaceuticals, and Regeneron Pharmaceuticals; is currently an expert panel member of myasthenia gravis consortium for argenx, has worked as chief or principal investigator for myasthenia trials by Alexion Pharmaceuticals, argenx, Momenta Pharmaceuticals, and UCB and has received speaker fees from Terumo Blood and Cell Technologies and Eisai, unrelated to this Correspondence. ACG has received research support from the Myasthenia Gravis Foundation of America and Myasthenia Gravis Rare Disease Network; clinical trial funding and consultant fees or honoraria from Momenta Pharmaceuticals, Ra Pharmaceuticals, and Alexion Pharmaceuticals; and publishing royalties from Oakstone Publishing, unrelated to this Correspondence. JFHJ has received research support from Alexion Pharmaceuticals, argenx, the Centers for Disease Control and Prevention (Atlanta, GA, USA), the Muscular Dystrophy Association, the National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, Ra Pharmaceuticals; honoraria from Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals, Regeneron Pharmaceuticals, and Viela Bio; and non-financial support from Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals, and Toleranzia, unrelated to this Correspondence. GC reports personal fees from MedDay Pharmaceuticals during the conduct of the study; personal fees for data safety monitoring boards from AstraZeneca, Avexis, BioLineRx, BrainStorm Cell Therapeutics, Bristol Myers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Horizon Pharmaceuticals, Hisun Pharmaceuticals, Mapi Pharmaceuticals, Merck, Merck/Pfizer, Opko Biologics, Neurim, Novartis, Ophazyme, Sanofi-Aventis, Reata Pharmaceuticals, Teva Pharmaceuticals, Viela Bio, Vivus, National Heart, Lung, and Blood Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, unrelated to this Correspondence; personal fees for consulting or advisory board from Biogen, Click Therapeutics, Sanofi Genzyme, Genentech, GW Pharmaceuticals, Klein-Buendel, MedImmune, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Recursion Pharmaceuticals/CereXis, Roche, Somahlution, and TG Therapeutics; and personal fees from Pythagoras, unrelated to this Correspondence. HW reports grants and personal fees from Abbvie, Biogen, Merck Serono, Sanofi Genzyme; personal fees from Evgen, MedDay Pharmaceuticals, Novartis, Roche Pharmaceuticals, Immunic, Alexion Pharmaceuticals, Actelion, F Hoffmann-La Roche, Gemeinnützige Hertie-Stiftung, Lundbeck, Teva Pharmaceuticals, WebMD Global; grants from Federal Ministry for Education and Research, Deutsche Forschungsgesellschaft, Else Kröner Fresenius Foundation, EU, Fresenius Foundation, Hertie Foundation, North Rhine-Westphalia Ministry of Education and Research, Interdisciplinary Center for Clinical Studies Muenster, Rasmussen's Encephalitis Children's Foundation, Progressive Multifocal Leukoencephalopathy Consortium, Swiss Multiple Sclerosis Society, and GSK, unrelated to this Correspondence. MBM receives grant funding from the National Institutes of Health and the Agency for Healthcare Research and Quality, unrelated to this Correspondence. HM reports personal fees from Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals, and UCB; and grants from Japan Blood Products Organization and Ministry of Health, Labour and Welfare, Japan, unrelated to this Correspondence. KU has served as a paid consultant for argenx, Ra Pharmaceuticals, UCB, and Viela Bio and has received speaker honoraria from the Japan Blood Products Organization and Alexion Pharmaceuticals, unrelated to this Correspondence. RJN has received research support from Alexion Pharmaceuticals, argenx, Genentech, Grifols, Immunovant, Momenta Pharmaceuticals, the Myasthenia Gravis Foundation of America, the National Institutes of Health (National Institute of Neurological Disorders and Stroke and National Institute of Allergy and Infectious Diseases), and Ra Pharmaceuticals; and consultancy fees from Alexion Pharmaceuticals, argenx, CSL Behring, Grifols, Immunovant, Momenta Pharmaceuticals, Ra Pharmaceuticals, Roivant Sciences, and Viela Bio, unrelated to this Correspondence. RM has received funding for travel or meeting attendance from Alexion Pharmaceuticals, argenx, Biomarin Pharmaceuticals, Novartis, Catalyst Pharmaceuticals, Merck Serono, and UCB and for advisory board participation from Alexion Pharmaceuticals, argenx, UCB, and Regeneron Pharmaceuticals. All other authors declare no competing interests. SM, JTG, and RJN contributed equally.
PY - 2020/12
Y1 - 2020/12
UR - http://www.scopus.com/inward/record.url?scp=85096457625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096457625&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(20)30413-0
DO - 10.1016/S1474-4422(20)30413-0
M3 - Letter
C2 - 33212055
AN - SCOPUS:85096457625
SN - 1474-4422
VL - 19
SP - 970
EP - 971
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 12
ER -